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Abstract  
AIM: The study aimed to identify factors that influence the positivity of axillary lymph nodes in patients with early 
breast cancer and clinically negative axillary lymph nodes, who were subjected for modified radical mastectomy 
and axillary lymphadenectomy. 
MATERIAL AND METHODS: This study included 81 surgically treated, early breast cancer patients during the 
period from 08-2015 to 05-2017. All the cases have been analysed by standard histological analysis including 
macroscopic and microscopic examination by routine H&E staining. For determination of molecular receptors, 
immunostaining by PT LINK immunoperoxidase has been done for HER2neu, ER, PR, p53 and Ki67.  
RESULTS: Patients age ranged between 31-73 years, an average of 56.86 years. The mean size of a primary 
tumour in the surgically treated patient was 20.33 ± 6.0 mm. Axillary dissection revealed from 5 to 32 lymph 
nodes, with an average of 14. Metastases have been found in 1 to 7 lymph nodes, with an average 0.7. Only 26 
(32.1%) of the patients showed metastases in the axillary lymph nodes. The univariant regression analysis 
showed that the size of a tumour and presence of HER2neu receptors on cancer cells influence the positivity of 
the axillary lymph nodes. The presence of the estrogen receptors, progesterone receptors have no influence on 
the positivity for metastatic deposits of lymph nodes. Multivariant model and logistic regression analysis as 
significant independent factors or predictors of positivity of the axillary lymph nodes are influenced by the tumour 
size only. 
CONCLUSION: Our study showed that the metastatic involvement of the axillary lymph nodes is mainly 
influenced by the size of a tumour and presence of HER2neu receptors in the univariant analysis. This point to the 
important influence of positivity of the axillary lymph nodes but, in multi-variant regressive analysis the lymph node 
status correlates with the tumour size only. 
 
 
Introduction 
 
Axillary status (involvement of lymph nodes in 
axilla with a metastatic tumour from primary breast 
cancer) together with the size of a primary breast 
tumour is the main factors that define the stage of 
breast cancer but also predict prognosis of the breast 
cancer [1].  
Introducing procedure – detection of sentinel 
node and biopsy, is a minimally invasive procedure 
that determines first drainage lymph node in the axillar 
pit [2]. Examination of this lymph node at the same 
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surgical intervention gives us information about the 
status of this lymph node but also gives us information 
about other lymph nodes in the axilla. We suppose 
that if the sentinel lymph node is negative (not 
involved with metastases), we suppose that all other 
lymph nodes in the axillary pit is negative and is not 
necessary to do lymphadenectomy. Knowing the 
status of the axillary lymph nodes is very important, 
for the planning further therapeutic procedure. 
The study aimed to analyse which factors that 
influence the positivity of axillary lymph nodes, with a 
point to tumour size, expression of estrogen, 
progesterone and HER2neu receptors on tumour cell 
surface, values of Ki67, in patients with early breast 
cancer and clinically negative axillary lymph nodes. 
 
 
Material and Methods  
 
In the prospective study were analyse 81 
surgically treated patients with early breast cancer 
during 08.2015-05.2017 year, with clinically negative 
axilla, at which were done a radical surgical 
intervention of the breast with complete axillary 
lymphadenectomy. All the cases have been analyzed 
by standard histological analysis including 
macroscopic and microscopic analysis of standard 
H&E staining. For determining of molecular receptors 
immunostaining by PT, LINK immunoperoxidase has 
been done for HER2neu, ER, PR, p53 and Ki67.  
Statistical analysis was done with statistical 
program Statistica 7. 
 
 
Results 
 
Patients age ranged between 31-73 years, an 
average of 56.86. The stages of the primary breast 
cancer in our patients are given in Table 1. The 
biggest frequency was found for stage IIA (41.97%), 
stage IA (29.63%), and for stage IIB (23.46%). We 
found stage IIA in 2.47%, the stage 0 in1.23%, and 
stage IB in 2.23%. We did not find any cases in 
stages IIIB and IIIC. 
Table 1: Stages of the primary breast cancer in our patients 
Variable Total 
(No = 81) (100.00%) 
Stage  
0 1 (1.23%) 
IA 24 (29.63%) 
IB 1 (1.23%) 
IIA 34 (41.97%) 
IIB 19 (23.46%) 
IIIA 2 (2.47%) 
IIIB 0 (0.00%) 
IIIC 0 (0.00%) 
 
Characteristics of the primary breast cancer in 
our patients are shown in Table 2. There were not 
found statically significant differences between axilla 
positive and axilla negative patients for tumour size, 
location, and histology. Nuclear grade was 
significantly diferent in the patients with axillary 
negative patients, where patients with G1 were 
(10.91%) and with G3 were (1.82%) in comparison 
with the positive axillary patients, where patients with 
G1 were (0%), and with G3 were (11.54%), (p < 
0.044). The mean size of a primary tumour in the 
surgically treated patient was 20.33 + 6.0 mm. On 
dissection from the axillary pits, there were taken out 
5 to 32 lymph nodes, an average of 14.0. Metastases 
have been found in 1 to 7 lymph nodes, an average 
0.7. In 32.1% of the patients have been found 
metastases in the axillary lymph nodes (Table 2). 
Table 2: Characteristics of the primary breast cancer in our 
patients 
Variable 
Axilla positive 
(N = 26) 
(32.1%) 
Axilla negative 
(N = 55) 
(67.9%) 
Total 
(N = 81) 
(100.00%) 
P 
Tumor size     
Tis 0 (0.00%) 1 (1.82%) 1 (8.40%) 
0.540 
T1a 0 (0.00%) 3 (5.45%) 3 (3.70%) 
T1b 0 (0.00%) 8 (14.54%) 8 (9.87%) 
T1c 5 (19.23%) 16 (29.09%) 21 (25.92%) 
T2 21 (80.76%) 27 (49.09%) 48 (59.25%) 
Location     
Central 5 (19.23%) 10 (18.18%) 15 (18.52%) 
0.991 Inner 4 (15.38%) 9 (16.36%) 13 (16.05%) 
Lateral 17 (65.38%) 36 (65.45%) 53 (65.43%) 
Histology     
Ductal 21 (80.77%) 46 (83.64%) 67 (82.72%) 
0.807 Lobular 3 (11.54%) 4 (7.28%) 7 (8.64%) 
Other 2 (7.69%) 5 (9.09%) 7 (8.64%) 
Nuclear grade     
1 0 (0.00%) 6 (10.91%) 6 (7.41%) 
0.044* 2 23 (88.46%) 48 (87.27%) 71 (87.65%) 
3 3 (11.54%) 1 (1.82%) 4 (4.94%) 
*, Statistically significant differences; N = number. 
 
The univariant regression analysis showed 
that the size of a tumour (p = 0.022) and presence of 
HER2neu receptors on cancer cell (p = 0.037) 
influence on the positivity of the axillary lymph nodes. 
Table 3: Characteristics of receptors in the primary breast 
cancer in our patients 
Variable 
Axilla positive 
(N=26) 
(32.1%) 
Axilla negative 
(N = 55) 
(67.9%) 
Total 
(N = 81) 
(100.00%) 
P 
Estrogen receptors     
Positive 22 (84.61%) 45 (87.82%) 67 (82.71%) 
0.755 
Negative 4 (15.38%) 10 (18.18%) 14 (17.28%) 
Progesterone receptors     
Positive 18 (69.23%) 41 (74.54%) 59 (72.84%) 
0.615 
Negative 8 (30.77%) 14 (25.45%) 22 (27.16%) 
Her 2neu receptors     
Positive 13 (50.00%) 21 (38.18%) 34 (41.97%) 
0.314 
Negative 13 (50.00%) 34 (61.82%) 47 (58.02%) 
P53     
Positive 11 (42.31%) 26 (47.27%) 37 (45.68%) 
0.675 
Negative 15 (57.69%) 29 (52.73%) 44 (54.32%) 
LVI     
Positive 15 (57.69%) 5 (9.09%) 20 (24.69%) 
< 0.001* 
Negative 11 (42.31%) 50 (90.91%) 61 (75.31%) 
Ki67     
< 20 11 (42.31%) 24 (43.64%) 35 (43.21%) 
0.910 
> 20 15 (57.69%) 31 (56.36%) 46 (56.79%) 
*, Statistically significant differences; N = number. 
  
Characteristics of the receptors in the patients 
with primary breast cancer are shown in Table 3. The 
presence of the estrogen receptors, progesterone 
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receptors showed that they do not have influence on 
the positivity for metastatic deposits in axillary lymph 
nodes, except the frequency of LVI positive patients 
(57.69%) in positive axillary patients in comparison 
with axillary negative patients (9.09%), (p < 0.001) 
(Table 3).  
Multivariant model and logistic regression 
analysis as significant independent factors or 
predictors of positivity of the axillary lymph nodes are 
influenced by the tumour size only (p = 0.014). 
 
 
Discussion 
 
Axilar lymphadenectomy gives us parameters 
for the axillar status, but at the same time is the 
therapeutic procedure. On the other hand, axillar 
lymphadenectomy was followed with many unlike 
features and complications like as sensation in the 
arm, reduction of the arm mobility and lymphedema 
[3]. Use the thesis of the Fisher and Veronesi that 
breast cancer is the systemic disease at the moment 
of the diagnosis it, and needs to be treated as a 
systemic disease with drugs that work in the whole 
body (chemotherapeutic, antihormonal therapy, 
immunotherapy) [4, 5]. So axillar status is a first 
diagnostic tool, and in many instances especially if it 
is not involved with metastatic disease, which is in 40-
70% not involved, it is not necessary to done axillar 
lymphadenectomy [6]. 
Prediction of axillary status can be used to 
predict whole axillar status, predict sentinel node and 
predict nonsentinel node status if sentinel node is 
positive [7-10]. 
Many authors use many standard methods for 
prediction of the axillar status, as clinical examination, 
mammography, ultrasonography, but also introduce 
new methods like ultrasound guide biopsy, CT, NMRI, 
Pet-CT, SPET-CT, contrast examinations, but in any 
case they see enlarged lymph nodes, but is 
impossible to guarantee that all this are metastatic 
changed (low sensitivity) [11-14]. Use of these 
methods is possible only to lower rate of falls negative 
results [15]. 
In last period we done lot investigations how 
different factors influent to positivity of axillary lymph 
nodes, on different groups of patients (patients with 
early breast cancer, patients with early breast cancer 
and clinically negative axilla, all surgically treated 
patients with breast cancer, patients with advanced 
breast cancer) and in last period we examined how 
size of tumor, persistence of estrogen receptors, 
progesterone receptors, HER 2 new receptors and 
Ki67 values influent to chance of dispersion of the 
disease in the axilla. Interesting is the fact that in the 
same institution in the same period, but on different 
groups of patients according to the stage of the 
disease were analysed the factors that can predict 
positivity of axilla. We find that in the whole group 
where patients with early but also with advantage 
stage were an as important factor for appearing 
metastases in axilla were the persistence of 
lymphovascular invasion and bigger values of Ki67 
that were not important in groups with only early 
breast cancer. The possibility is that with the 
advantage of the stage are appearing aggressive 
factors in a tumour that after that influence on 
spreading the tumour cells in lymph nodes in axilla 
[16, 17]. 
Introduction of SLND detection, especially if 
are used both type of detection, as vital blue due 
(methylene blue) and radioisotope Technician with 
colloid particles (radiocoloid) at the end of the last 
century, give us very successful tool for detection 
SLND, which histological examination, give us 
successfully status of SLND but also status of whole 
axilla [16, 18-22].  
In literature, there are many investigations for 
determination of factors that can predict positivity of 
axilla, SLND and NSLND if SLND is positive. Factors 
can be divided into few categories: 
- Epidemiological (age, race, side, localisation); 
- Clinical (palpability of a tumour, palpability of 
axillary lymph nodes, location); 
- Pathological (histology of a tumour, 
differentiation of cells, neovascularisation of a 
tumour, vascular and lymphovascular 
invasion, extensive intraductal component, 
the persistence of receptors on the surface of 
the cells- estrogen, progesterone, Her-2 new, 
the persistence of p53 proteins, the 
persistence of factor of proliferation Ki67. 
Knowing these parameters is possible to 
determine subtype of breast cancer.); 
- Biochemical (CEA, CA 15-3); 
- Genetic (BRCA1, BRCA2, VEGFC, MIB1, 
CCR7, CXCR4 ) [23-59]. 
Many of the factors that were examined as a 
predictor of axillary status, is very well known, known 
is a biological way of action, and is very well known 
how is their action to the biology of a tumour, and how 
they work to spread the disease in the body. So 
estrogen receptors are on the surface of the cell. The 
connection of the estrogen and estrogen receptors 
activate many processes in the cell and favourite 
raising and dividing the cells, so favourite estrogen 
rising of a tumour. Giving the drugs that blockade 
estrogen receptors or drugs that blockade synthesis of 
the estrogen will stop rising of a tumour. The same 
situation is with persistence of HER-2 neu receptors. 
HER2 is a membrane tyrosine kinase and oncogene 
that is overexpressed and gene amplified in about 
20% of breast cancers. When activated it provides the 
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cell with potent proliferative and anti-apoptosis 
signals, and it is the major driver of tumour 
development and progression of breast cancer. Over 
expression will activate many pathways in the cell, so 
the cells will raise and divide uncontrolled, so a 
tumour will raise and can’t be under control. Giving 
the target drug – monoclonal antibody-Trastuzumab 
(Herceptin), will blockade this receptor, and the 
tumour will be under control. More, giving 
chemotherapeutics which interact with all cells which 
is divide fast; a tumour will be under control. Ki67 is a 
factor that shows the proliferative activity of the 
tumour cells. Ki67 is in correlation with S phase of 
cells and mitotic activity. Normal breast cell has a 
proliferative activity of 3% (3% of cells are in dividing 
stage). The Bigger activity of 20 % shows an 
aggressive tumour with bad prognosis and shorter 
survival [60-62]. 
Many investigators analyse many factors, how 
to allow or in combination can predict the status of the 
axillar lymph nodes, the status of SLND and in recent 
time status of NSLND. Postaci, Jiao, Jaime Jans, 
Ugras, Gangi, Pijnappel, Sawaki, Brenin, Chung, 
Chadha, Tan, Gajdos, Qiu, Ashturkar, Wu, Tseng, Ko, 
Li, Ngo, Yoo, Danko, Cabioglu, Capdet, Susini, 
Wasuthit are part of authors whose in last decade 
investigate which factors influent to positivity of axillar 
lymph node or positivity of sentinel node. They 
investigate all factors that can be investigated like 
epidemiological, clinical, histopathological, genetic, 
molecular. Mainly from all these studies dominantly 
main factors that can influent to positivity of axillar 
nodes are the size of a tumour, location, histology, 
grade of differentiation, lymphovascular invasion. But 
also in many of the investigations, other factors that 
can influence to positivity of axillar lymph nodes are 
referred: age, the persistence of estrogen, 
progesterone and Her two new receptors on the 
surface of the cells, a subtype of breast cancer, 
values of Ki67, multifocality, EIC and other. In only a 
few studies were referred VEGFC, MIB1, CEA, CA 
15-3, CCR7, CXCR4 and others [23-46]. 
It is very interesting how some factors in 
some studies are important factors that predict axillar 
involvement with metastases, but in other studies, 
these factors are not important, and no influence to 
axillar involvement. For example in studies of Jiao, 
Pijnappel, Sawaki, Gangi, Qiu one of the essential 
factors that predict axillar involvement is the 
persistence of hormonal receptors and HER 2 
receptors on the tumour cell, much more is well 
defined that Luminal and Her enriched tumours lymph 
nodes are more often involved with metastatic 
disease. On the other hand, triple negative tumours 
rarely have involvement of lymph nodes with 
metastatic disease, never less than this type shows 
early distant metastasis and worse prognosis. But in 
many others, studies show that persistence of 
hormone receptors, HER 2 receptors on the surface of 
tumour cells, does not influence involvement of 
axillary lymph nodes with metastases. So it is 
interesting why the same factor in one study is the 
main factor, and in other study is not important [24, 
27-29, 35]. 
In our study, the univariant regression 
analysis showed that the size of a tumour and 
presence of HER2 neu receptors on the surface of 
cancer cell influence on the positivity of the axillary 
lymph nodes. The presence of the estrogen receptors 
and progesterone receptors showed that they do not 
have an influence on the positivity for metastatic 
deposits in axillary lymph nodes. Multivariant model 
and logistic regression analysis as significant 
independent factors or predictors of positivity of the 
axillary lymph nodes are influenced by the tumour size 
only. It is necessary as a minimum to done detection 
and biopsy of the sentinel node, which is further 
histology examined. With detecting status of the 
sentinel node, we can safely predict the status of 
other lymph nodes in the axilla. 
In conclusion, our study showed that the 
involving of the axillary lymph nodes is mainly 
influenced by the size of a tumour and presence of 
HER2neu receptors in the univariant analysis points 
the important influence of positivity in the axillary 
lymph nodes but the only size of a tumour in the 
multivariate regressive analysis.  
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